Teladoc Health Stock Forecast

Stock Price Forecast

According to 25 analysts polled by S&P Global, Teladoc Health stock has a consensus rating of "Buy" and an average price target of $7.40. The average 1-year stock price forecast is 19.57% lower than the current stock price, while the lowest is $5.00 (-45.65%) and the highest is $10 (+8.70%).

Price Target: $7.40 (-19.57%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.00	$7.40	$7.00	$10
Change	-45.65%	-19.57%	-23.91%	+8.70%

* Price targets were last updated on May 29, 2026.

Analyst Ratings

The average analyst rating for Teladoc Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	5	6	6	6	6
Buy	1	1	1	1	1	1
Hold	22	21	19	19	19	18
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	27	27	26	26	26	25

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jailendra Singh Truist Financial	Truist Financial	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Jul 2, 2026
Allen Lutz Bank of America Securities	Bank of America Securities	Buy Maintains $8.25 → $9	Buy	Maintains	$8.25 → $9	-2.17%	May 29, 2026
David Roman Goldman Sachs	Goldman Sachs	Buy Maintains $7 → $8	Buy	Maintains	$7 → $8	-13.04%	May 27, 2026
Kevin Caliendo UBS	UBS	Hold Maintains $6	Hold	Maintains	$6	-34.78%	May 15, 2026
Daniel Grosslight Citi	Citi	Hold Reiterates $6 → $7	Hold	Reiterates	$6 → $7	-23.91%	May 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

2.51B

from 2.53B

-0.96%

from 2.53B

Revenue Next Year

2.54B

from 2.51B

1.25%

from 2.51B

EPS This Year

-0.79

from -0.66

EPS Next Year

-0.65

from -0.79

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	2.03B	2.41B	2.60B	2.57B	2.53B	2.51B
Revenue Growth	85.81%	18.41%	8.13%	-1.26%	-1.54%	-0.96%
Gross Profit	1.38B	1.66B	1.84B	1.82B	1.76B	1.72B
Gross Margin	68.01%	69.09%	70.80%	70.76%	69.50%	68.73%
Operating Income	-238.99M	-217.47M	-210.50M	-208.79M	-163.40M	-169.32M
Net Income	-428.79M	-13.66B	-220.37M	-1.00B	-200.32M	-165.72M
EPS	-	-	-	-	-0.66	-0.79
Free Cash Flow	241.62M	176.62M	303.95M	229.78M	226.14M	144.37M
No. Analysts	-	-	-	-	-	23

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	2.5B
Avg	2.5B
Low	2.5B

Revenue Growth

Revenue Growth	2026	2027	2028
High	0.1%
Avg	-1.0%
Low	-1.9%

EPS Forecast

EPS	2026	2027	2028
High	-0.61
Avg	-0.79
Low	-0.89

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-